北京若生智能科技有限公司
Drug Database
SI

simvastatin + triflusal (IRIST stent)

✓ Approved

Palau Pharma · HMGCR · 小分子

什么是 simvastatin + triflusal？

simvastatin + triflusal 是一种小分子，由Palau Pharma研发。该药已获批，用于治疗相关适应症，给药途径：Surgical Implantation。

药物档案

商品名IRIST stent
公司Palau Pharma
药物类别小分子
分子靶点HMGCR, PDE4A, PDE4B, PDE4C, PDE4D, PTGS1, PTGS2
给药途径Surgical Implantation
状态Approved
来源： ClinicalTrials.gov, Palau Pharma

作用机制

分子靶点

simvastatin + triflusal 作用于 7 个分子靶点：

HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, MYPLG)
PDE4Aphosphodiesterase 4A (PDE4, DPDE2)
PDE4Bphosphodiesterase 4B (PDEIVB, DPDE4)
PDE4Cphosphodiesterase 4C (DPDE1, PDE21)
PDE4Dphosphodiesterase 4D (PDE43, STRK1)
PTGS1prostaglandin-endoperoxide synthase 1 (PCOX1, COX3)
PTGS2prostaglandin-endoperoxide synthase 2 (PHS-2, GRIPGHS)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

simvastatin + triflusal 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Injury, poisoning and procedural complicationsRestenosis✓ Approved

相关研究文献

PubMedBMC anesthesiology2026-10-26

Emergency airway management of a relapsing polychondritis patient with tracheal stent migration: a case report.

Sun Zhongliang Z, Zhang Lingxue L, He Runjuan R, Zhang Yu Y et al.

Relapsing polychondritis (RP) is a rare autoimmune disorder characterized by recurrent inflammation of cartilaginous structures, frequently involving the tracheobronchial tree. Progressive airway involvement may result in tracheal stenosis and tracheobronchomalacia, often necessitating airway stent placement. Airway management in these patients is particularly challenging, especially in the presence of stent-related complications such as migration. A 71-year-old man with RP and a history of tracheobronchial stent placement presented with respiratory distress following a traumatic fall. Emergency tracheal intubation was indicated due to progressive hypoxemia. Computed tomography (CT) revealed cephalad migration of the tracheal stent, resulting in misalignment between the stent lumen and the native airway. Rapid sequence induction was performed under video laryngoscopy. During intubation, significant gastroesophageal regurgitation occurred. A 7.0-mm endotracheal tube was initially positioned with the cuff at the level of the vocal cords to reduce the risk of aspiration. After thorough suctioning of gastric contents, the tube was advanced into the stent lumen under flexible bronchoscopic guidance. Bronchoscopy revealed airway collapse consistent with tracheobronchomalacia and impaired ventilation of the right lung due to stent malposition. Attempts to reposition the stent were unsuccessful. The patient subsequently developed severe pulmonary infection and acute respiratory distress syndrome (ARDS) and died two weeks later. Emergency airway management in patients with tracheal stents is technically challenging, particularly in the presence of stent migration. Bronchoscopic guidance is essential to ensure proper alignment of the endotracheal tube with the stent lumen. Clinicians should anticipate altered airway anatomy and be prepared for complex airway interventions.

PMID 42928126
阅读全文 →
PubMedCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026-10-26

Evaluation of CardiaZn Pediatric Biodegradable Stent in a Long-Term Animal Model.

Levi Daniel S DS, Latson Larry L, Stoffregen William C WC, Bocks Martin M et al.

A survey of interventional pediatric cardiologists identified bioresorbable stents for aortic and pulmonary coarctations as the most needed device. PediaStent developed the CardiaZn stent and conducted a 2.5-year GLP preclinical study to evaluate device safety, biocompatibility, and functional performance. Twelve Yucatan (17-23 kg) mini swine received two CardiaZn stents in the aorta and one in the pulmonary artery with terminal assessments performed at 3, 28, 360, 540, 730, and 902 days. At 180 days, all remaining animals underwent catheterization, with an additional CardiaZn stent placed over a previous aortic stent in four subjects. All subjects received CT scans at 1 year. There were no stent migrations, evidence of vessel injury, angiographic obstruction, or stent fragment embolization. From 180 to 360 days, the pulmonary artery, sub-renal, and supra-iliac aortic stents increased in diameter by 18%, 24%, and 28%, on average, respectively. Simultaneously, the pulmonary and sub-renal aortic stents elongated by an average of 40%. All CardiaZn stents explanted from 28 through 902 days were completely endothelialized. Histopathology displayed moderate remodeling of the tunica media without loss of structural integrity or extension into the adventitia. MicroCT analysis showed loss of mass and structural integrity secondary to degradation resulting in stent cell disconnection, allowing for vessel growth by 9-12 months. The CardiaZn stent provided vascular support for up to 9 months before safely degrading to allow for vascular growth. A clinical trial is planned to confirm safety and efficacy in children.

PMID 42928495
阅读全文 →
PubMedCureus2026-10-26

When the Gallbladder Hurts the Thigh: Silent Gallbladder Empyema With Perforation Presenting as Severe Rhabdomyolysis.

Loo Enzhong E, Khit Kar Hui KH

Gallbladder empyema and perforation are severe complications of acute cholecystitis that typically present with abdominal pain, fever, and systemic inflammation. However, clinically silent or atypical presentations may occur, particularly in older patients with diabetes and multiple comorbidities, potentially resulting in delayed diagnosis. This is a case of gallbladder empyema complicated by perforation and biliary leakage that presented predominantly with severe thigh pain and rhabdomyolysis, in the absence of abdominal symptoms. A 71-year-old man with type 2 diabetes mellitus, peripheral vascular disease, chronic kidney disease, ischaemic heart disease, and heart failure with reduced ejection fraction presented with fever, generalised weakness, severe right thigh pain, and inability to mobilise. He consistently denied abdominal pain. Initial investigations revealed marked systemic inflammation, with a white cell count of 28-32 × 10⁹/L and a C-reactive protein (CRP) of 580-616 mg/L. He had acute kidney injury (peak creatinine 406 μmol/L), hyperphosphataemia, and a markedly raised creatine kinase (CK) of 16,697 U/L, consistent with rhabdomyolysis (McMahon score > 6). MRI of the pelvis and femurs demonstrated bilateral, right-predominant muscle oedema without evidence of an intramuscular collection. Non-contrast CT of the abdomen revealed a markedly distended and inflamed gallbladder with adjacent subcapsular and perihepatic collections suggestive of gallbladder perforation with biliary leakage. Ultrasound-guided drainage of the perihepatic collection yielded bilious fluid. The gallbladder empyema was subsequently managed with endoscopic ultrasound-guided cholecystogastrostomy using a Hot AXIOS lumen-apposing metal stent (Boston Scientific Corp., Natick, MA, USA), allowing drainage of purulent bile. Subsequent endoscopic washout was performed, with placement of two pigtail stents through the AXIOS stent. Following antibiotic treatment and biliary source control, inflammatory markers, CK, and renal function improved, with resolution of the thigh pain and improvement in mobility, allowing discharge home. Gallbladder empyema complicated by perforation can occur without abdominal pain and may present predominantly with extra-abdominal features. In older patients with diabetes and multiple comorbidities who present with unexplained sepsis, an occult intra-abdominal source should be considered even when abdominal symptoms and signs are absent. Although the direct mechanism linking biliary infection to rhabdomyolysis remains uncertain, the parallel resolution of sepsis, CK, renal function, and thigh pain after antibiotic treatment and biliary drainage supports the infection as the unifying driver. This case also demonstrates that endoscopic ultrasound-guided gallbladder drainage with a lumen-apposing metal stent offers an effective and minimally invasive alternative to surgery for source control in patients with high operative risk.

PMID 42928850
阅读全文 →
PubMedCureus2026-10-26

Ticagrelor-Induced Bradyarrhythmias in Acute Coronary Syndrome: A Case Series of Three Patients.

Molleti Ashish A, Sankaran Ramesh R, Vinod Kumar Balakrishnan B, Arul Judah N JN

Ticagrelor is a reversible oral P2Y12 receptor inhibitor recommended in preference to clopidogrel for most patients with acute coronary syndrome. In addition to inhibiting platelets, it raises extracellular adenosine, which is thought to explain its underappreciated capacity to cause bradyarrhythmia. We report three consecutive patients with acute coronary syndrome who developed serious bradyarrhythmias after ticagrelor administration. The first, a 58-year-old woman treated with a drug-eluting stent to the left anterior descending artery, developed high-grade atrioventricular block with asystolic pauses that required a temporary pacing wire, after which ticagrelor was stopped, prasugrel was substituted, and she recovered. The second, a 48-year-old woman with an anterior myocardial infarction, had a cardiac arrest with complete heart block after ticagrelor loading, was resuscitated, paced temporarily, switched to prasugrel, and recovered. The third, a 77-year-old man with an inferoposterior and right ventricular myocardial infarction, had recurrent asystole and ventricular arrhythmia that persisted despite switching to prasugrel and required a permanent pacemaker. None of the patients were receiving an atrioventricular nodal blocking drug, and in every patient the treated coronary lesion was patent on a repeat angiogram, which made ongoing ischemia from stent failure an unlikely sole explanation. A formal Naranjo assessment rated the association as possible in each case. A ticagrelor-induced adverse effect should be considered in any patient who develops unexplained bradycardia or syncope after its administration. Early rhythm monitoring and prompt withdrawal are the key steps, and although the rhythm usually recovers, permanent pacing may be needed when conduction disease is superimposed on ischemic injury to the conduction system.

PMID 42928934
阅读全文 →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-10-26

Restoring Endothelial Mitochondrial Homeostasis With a Bioactive Nanoshield Promotes Vascular Regeneration on Cardiovascular Implants.

Liu Xiyu X, Zhang Wen W, Liu Lunxin L, Gui Lan L et al.

Defective endothelial regeneration constitutes a fundamental barrier to durable vascular repair. By integrating single cell RNA-sequencing data from rat carotid balloon injury with ultrastructural and histological evidence from rabbit stented arteries, we identified mitochondrial disorganization and dysfunction as common features of injured endothelial cells. Guided by these findings, we developed a poly(citrate-polyglycol-procyanidin) (PCGP) nanoshield to couple mitochondrial protection with anticoagulant and immunoregulatory functions for cardiovascular devices. PCGP preserved mitochondrial integrity, restored endothelial metabolic homeostasis, and rescued the regenerative phenotype of endothelial cells under oxidative stress. In rabbit arterial stent models, this intervention reactivated the PI3K/AKT/eNOS-nitric oxide axis, accelerated functional re-endothelialization, and markedly suppressed neointimal hyperplasia. Collectively, these findings support restoration of endothelial mitochondrial homeostasis as an important mechanistic axis associated with vascular repair.

PMID 42928428
阅读全文 →
PubMedRevista espanola de enfermedades digestivas2026-10-26

From Baveno VII to Baveno VIII: key innovations in risk stratification and personalized care for portal hypertension.

Téllez Luis L, Donate Ortega Jesús J, Fortea José Ignacio JI, Baiges Anna A et al.

Portal hypertension is a major determinant of disease progression and clinical outcomes in cirrhosis. The Baveno consensus has progressively moved its focus from the treatment of established complications towards earlier risk stratification, prevention of decompensation and modification of the natural history of the disease. Baveno VIII consolidates and extends this approach across the different stages of advanced chronic liver disease. Non-invasive assessment of clinically significant portal hypertension is refined through the incorporation of spleen stiffness measurement and probabilistic models, while longitudinal assessment emphasizes the importance of updating risk according to the most recent evaluation. In compensated disease, prevention of first decompensation remains centred on aetiological treatment and carvedilol in patients with clinically significant portal hypertension, together with management of relevant modifiable factors. In decompensated cirrhosis, greater emphasis is placed on preventing further decompensation and considering transjugular intrahepatic portosystemic shunt (TIPS) earlier in the disease course, with individualized patient selection, stent diameter and strategies to prevent and manage post-TIPS hepatic encephalopathy. Management of acute portal hypertension-related bleeding is further refined, particularly regarding the timing of pre-emptive TIPS and the treatment of gastric varices and vascular gastric lesions. Finally, updated criteria for hepatic recompensation establish durable clinical recovery as a meaningful therapeutic goal. These advances support a more individualized approach to portal hypertension, integrating disease stage, risk of progression and response to treatment throughout the course of cirrhosis.

PMID 42929255
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多simvastatin + triflusal